<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>15</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Transducer-like Enhancer of Split 1 as a Novel Immunohistochemical Marker for Diagnosis of Synovial Sarcoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>6545</FirstPage>
			<LastPage>6548</LastPage>
			<ELocationID EIdType="pii">31439</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Synovial sarcoma is a mesenchymal neoplasm that accounts for around 10% of all softtissue sarcomas. The diagnosis of synovial sarcoma can be a challenging task, particularly with small biopsyspecimens. Aim: We investigated transducer-like enhancer of split 1 (TLE1), monoclonal antibody, expressionby immunohistochemical analysis in a group of 74 synovial sarcoma cases, 20 cases of MPNST, 12 cases ofneurofibroma, 15 cases of schwannoma, 5 cases of MFH, 10 cases of lieomyosarcoma and 10 cases of solitaryfibrous tumor. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Whole tissue sections were examined: (39 biphasic and 35 monophasic).Nuclear immunoreactivity was scored as negative (&lt;5% of cells positive), 1+(mild /5-25%), 2+ (moderate/25-50%),and 3+ (strong &gt;50%). &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Overall, 71 (96%) of 74 synovial sarcomas were positive for TLE1, including 37biphasic (95%) and 34 monophasic (97%) tumors. Other spindle cell tumors showed very low or absent stainingof TLE1. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: We conclude that TLE1 is a sensitive marker and can be a useful diagnostic marker forsynovial sarcoma, particularly the monophasic forms.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">TLE-1</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">synovial sarcomas</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">spindle cell sarcomas</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_31439_bfa0d4a5e88b76fc4d5af560d47b3862.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
